370 related articles for article (PubMed ID: 26240494)
1. Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea.
Kim SH; Seo HK; Shin HC; Chang SJ; Yun S; Joo J; Ku JH; Kim HS; Jeon HG; Jeong BC; Jeong IG; Kang SH; Hong B;
J Korean Med Sci; 2015 Aug; 30(8):1150-6. PubMed ID: 26240494
[TBL] [Abstract][Full Text] [Related]
2. Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.
Hermans TJN; Fransen van de Putte EE; Horenblas S; Lemmens V; Aben K; van der Heijden MS; Beerepoot LV; Verhoeven RH; van Rhijn BWG
Eur J Cancer; 2016 Feb; 54():18-26. PubMed ID: 26707593
[TBL] [Abstract][Full Text] [Related]
3. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS
Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710
[TBL] [Abstract][Full Text] [Related]
4. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
[TBL] [Abstract][Full Text] [Related]
5. Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Dogan S; Hennig M; Frank T; Struck JP; Cebulla A; Salem J; Borgmann H; Klatte T; Merseburger AS; Kramer M; Hofbauer SL
Urol Int; 2018; 101(1):25-30. PubMed ID: 29510388
[TBL] [Abstract][Full Text] [Related]
6. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
[TBL] [Abstract][Full Text] [Related]
7. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
8. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database.
Darwish C; Sparks A; Amdur R; Reddy A; Whalen M
Urology; 2020 Dec; 146():168-176. PubMed ID: 32866509
[TBL] [Abstract][Full Text] [Related]
9. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy.
Alvaeus J; Rosenblatt R; Johansson M; Alamdari F; Jakubczyk T; Holmström B; Hemdan T; Huge Y; Aljabery F; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442
[TBL] [Abstract][Full Text] [Related]
10. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
11. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
[TBL] [Abstract][Full Text] [Related]
12. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
13. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
15. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
[No Abstract] [Full Text] [Related]
16. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S
J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657
[TBL] [Abstract][Full Text] [Related]
17. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis.
Liu W; Tian J; Zhang S; Yang E; Shen H; Li F; Li K; Zhang T; Wang H; Svatek RS; Rodriguez R; Wang Z
Minerva Urol Nephrol; 2021 Apr; 73(2):144-153. PubMed ID: 31920065
[TBL] [Abstract][Full Text] [Related]
18. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
20. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
